Regenxbio Inc. (RB0)
XDUS 
Summary
RB0 Chart
People also search for
Regenxbio: 'Strong Buy' On FDA Course Reversal For NAVSUNLI And Potential AA DMD Filing
REGENXBIO upgraded to 'Strong Buy' on FDA's course reversal for rare disease therapies, notably impacting NAVSUNLI [RGX-121] for MPS II. Company expects to resubmit NAVSUNLI BLA in Q3 2026, leveraging robust CAMPSIITE trial data and no new study requirements per FDA alignment. RGX-202 for DMD and sura-vec for wet AMD offer additional catalysts, with pivotal trial data and regulatory submissions anticipated through 2027.
Regenxbio Shares Rise on Plans to Resubmit Navsunli BLA for MPS II
RGNX shares jump after FDA alignment on next steps for Navsunli, paving the way for a planned MPS II BLA resubmission in Q3 2026.
FDA Will Reverse Rejection of Third Rare-Disease Drug, Regenxbio Says
The company plans to refile its application for its gene therapy for a fatal brain disease after the FDA dropped demands to give a placebo to some study subjects.
Regenxbio Inc. (RB0) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Regenxbio Inc. ever had a stock split?
Regenxbio Inc. Profile
| Biotechnology Industry | Healthcare Sector | Curran Simpson CEO | XDUS Exchange | US75901B1070 ISIN |
| US Country | 371 Employees | - Last Dividend | - Last Split | 17 Sep 2015 IPO Date |
Overview
REGENXBIO Inc. is a front-runner in the clinical-stage biotechnology industry, specializing in the provision of pioneering gene therapies. Based in Rockville, Maryland, the company was established in 2008 and has been dedicated to addressing genetic defects through the delivery of functional genes into cells. This innovative approach is facilitated by their proprietary NAV Technology Platform, an adeno-associated virus gene delivery mechanism. This platform stands at the core of REGENXBIO’s operations, underpinning the development of its diverse range of gene therapy product candidates. These candidates target a variety of chronic and severe genetic diseases, asserting REGENXBIO’s pivotal role in the evolution of gene therapy in the United States. Furthermore, the company not only focuses on developing its own product lineup but also licenses this groundbreaking NAV Technology Platform to other entities within the biotechnology and pharmaceutical industries, enhancing the widespread applicability of its research and developments. The collaboration with AbbVie Global Enterprises Ltd. for the development of ABBV-RGX-314 outside the United States exemplifies REGENXBIO’s commitment to global health improvements through strategic partnerships.
Products and Services
ABBV-RGX-314: This innovative product candidate is a gene therapy aimed at treating wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases. ABBV-RGX-314’s development is in collaboration with AbbVie Global Enterprises Ltd., showcasing REGENXBIO’s strength in forming strategic partnerships to enhance its product offerings.
RGX-202: Currently in Phase I/II clinical trial, RGX-202 is designed to address Duchenne muscular dystrophy. This product highlights the company’s commitment to tackling severe genetic disorders and improving muscle function and quality of life for affected individuals.
RGX-121: Targeting mucopolysaccharidosis type II, RGX-121 is a gene therapy that is advancing through Phase III clinical trials. This product represents REGENXBIO’s efforts to address rare and serious genetic conditions with innovative gene transfer technologies.
RGX-111: Developed for the treatment of mucopolysaccharidosis type I, RGX-111 is another exemplar of the company’s dedication to combating rare genetic diseases through cutting-edge gene therapy solutions.
RGX-181: Focused on late infantile neuronal ceroid lipofuscinosis type II, RGX-181 is part of REGENXBIO’s pipeline aimed at treating rare neurological genetic conditions, demonstrating the company’s pursuit of solutions for complex genetic disorders.
RGX-381: Specifically developed to address the ocular manifestations of CLN2 disease, RGX-381 exemplifies REGENXBIO’s commitment to expanding its therapeutic reach into various aspects of genetic conditions, underlining the versatility and breadth of its product pipeline.
These products underline REGENXBIO Inc.'s forte in leveraging its NAV Technology Platform to address a spectrum of genetic disorders. By focusing on such diverse therapeutic areas, the company not only highlights its scientific and technical expertise but also underscores its commitment to improving patient outcomes across a range of challenging genetic conditions.
